



Resp. w/ Seq. Listing #11
J 5/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Docket No.: 186.009US1

Filed: August 11, 2000

Examiner: Stephen L. Rawlings, Ph.D.

RECEIVED

Serial No.: 09/637,530

Due Date: May 3, 2002

Group Art Unit: 1642

MAY 20 2002

SEQUENCE
BOX NON-FEE AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Arling ton, VA 22202

TECH CENTER 1600/2900

P.O. Box 2327

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Response to Notice to Comply (1 Page), with copy of Notice to Comply mailed 4/3/02 (1 pg).
- ☒ Replacement copies of documents originally filed February 1, 2002: Transmittal sheet (1 pg); Communication Under 37 CFR 1.821 (1pg); Sequence Listing (3 pgs); and ASCII Computer-Readable Sequence Listing (1 disk).

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann M. McCrackin

Atty: Ann M. McCrackin

Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231, on this 3rd day of May, 2002.

Candis B. Buending

Name

Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

S/N 09/637,530

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Examiner: Stephen L. Rawlings

Serial No.: 09/637,530

Group Art Unit: 1642

Filed: August 11, 2000

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents
Washington, D.C. 20231

This is in response to the Notice to Comply mailed April 4, 2002, requesting a replacement of the damaged sequence listing on diskette originally mailed February 1, 2002 in response to the Office Action mailed December 6, 2001.

Attached hereto are replacement copies of the following items originally submitted to the Office on February 1, 2002:

- Transmittal sheet (1 pg);
- Communication under 1.821 (1 pg);
- Sequence Listing (3 pgs); and
- Sequence Listing in computer-readable form (1 disk).

Applicant believes that all requirements of the Office Action mailed December 6, 2001 have now been met, and that no additional response or fee is required. However, any fee deemed to be due may be charged to Applicant's Deposit Account No. 19-0743.

The Examiner is invited to telephone Applicant's attorney (612-349-9592) if there are any questions concerning this communication.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592

Date May 3, 2002

By Ann M. McCrackin

Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 3rd day of May, 2002.

Candis B. Buending

Name

Signature

RECEIVED
MAY 20 2002
TECH CENTER 1600/2900



Notice to Comply

Application No.

09/637,530

Examiner

Stephen L. Rawlings, Ph D

Applicant(s)

STANNERS ET AL.

Art Unit

1642

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a))

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
MAY 20 2002
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Docket No.: 186.009US1

Serial No.: 09/637,530

Filed: August 11, 2000

Due Date: February 6, 2002

Examiner: Stephen L. Rawlings

Group Art Unit: 1642

Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Communication Under 37 CFR 1.821 (1 page).
- ☒ Sequence Listing (4 pgs.).
- ☒ ASCII Computer-Readable Sequence Listing (1 disk).
- ☒ Copy of Notice To Comply (from Paper No. 7) (1 page).
- ☒ Petition for one-month extension of time, with authorization to charge fee to Deposit Acct. 19-0743.

RECEIVED

MAY 20 2002

TECH CENTER 1600/2900

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann M. McCrackin
Atty: Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 1 day of February, 2002.

Candis B. Buending


Name

Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)



S/N 09/637,530

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Examiner: Stephen L. Rawlings

Serial No.: 09/637,530

Group Art Unit: 1642

Filed: August 11, 2000

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

COMMUNICATION UNDER 37 CFR § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office communication mailed December 6, 2001 (Paper No. 7), a SEQUENCE LISTING is submitted herewith, along with a copy of the Notice to Comply, as requested.

In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith.

It is respectfully submitted that the contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same.

It is further submitted that the paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not represent new matter.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592

Date Febr. 1, 2002

By Ann M. McCrackin


Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 1 day of February, 2002.

Candis B. Buending

Name

Candis B. Buending
Signature



Notice to Comply

Application No.	Applicant(s)	
09/637,530	STANNERS ET AL.	
Examiner	Art Unit	
Stephen I. Rawlings, Ph.D.	1642	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
MAY 20 2002
TECH CENTER 160012900